You can seek FDA approval to launch a generic drug before the expiration of AGGRASTAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AGGRASTAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AGGRASTAT:-

You can seek FDA approval to launch a generic drug before the expiration of ALIMTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALIMTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALIMTA:-

You can seek FDA approval to launch a generic drug before the expiration of AZOR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AZOR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AZOR:-

You can seek FDA approval to launch a generic drug before the expiration of BENICAR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BENICAR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BENICAR:-

You can seek FDA approval to launch a generic drug before the expiration of BENICAR HCT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BENICAR HCT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BENICAR HCT:-

You can seek FDA approval to launch a generic drug before the expiration of BROVANA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BROVANA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BROVANA:-

You can seek FDA approval to launch a generic drug before the expiration of CADUET's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CADUET's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CADUET:-

You can seek FDA approval to launch a generic drug before the expiration of CRESTOR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CRESTOR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CRESTOR:-

You can seek FDA approval to launch a generic drug before the expiration of CUBICIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the CUBICIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on CUBICIN:-

You can seek FDA approval to launch a generic drug before the expiration of ELOXATIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ELOXATIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ELOXATIN:-

You can seek FDA approval to launch a generic drug before the expiration of ENTEREG's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ENTEREG's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ENTEREG:-

You can seek FDA approval to launch a generic drug before the expiration of EPZICOM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EPZICOM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EPZICOM:-

You can seek FDA approval to launch a generic drug before the expiration of FANAPT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FANAPT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FANAPT:-

You can seek FDA approval to launch a generic drug before the expiration of GLUMETZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GLUMETZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GLUMETZA:-

You can seek FDA approval to launch a generic drug before the expiration of JEVTANA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JEVTANA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JEVTANA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of LASTACAFT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LASTACAFT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LASTACAFT:-

You can seek FDA approval to launch a generic drug before the expiration of LIPITOR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LIPITOR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LIPITOR:-

You can seek FDA approval to launch a generic drug before the expiration of LONSURF's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LONSURF's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LONSURF:-

You can seek FDA approval to launch a generic drug before the expiration of MEPRON's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MEPRON's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MEPRON:-

You can seek FDA approval to launch a generic drug before the expiration of MULTAQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MULTAQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MULTAQ:-

You can seek FDA approval to launch a generic drug before the expiration of NEXIUM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NEXIUM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NEXIUM:-

You can seek FDA approval to launch a generic drug before the expiration of NEXIUM 24HR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NEXIUM 24HR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NEXIUM 24HR:-

You can seek FDA approval to launch a generic drug before the expiration of RELPAX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the RELPAX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on RELPAX:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of REVLIMID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REVLIMID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REVLIMID:-

You can seek FDA approval to launch a generic drug before the expiration of SENSIPAR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SENSIPAR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SENSIPAR:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of TAMIFLU's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TAMIFLU's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TAMIFLU:-

You can seek FDA approval to launch a generic drug before the expiration of TRIUMEQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRIUMEQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRIUMEQ:-

You can seek FDA approval to launch a generic drug before the expiration of TRIZIVIR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRIZIVIR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRIZIVIR:-

You can seek FDA approval to launch a generic drug before the expiration of VALTREX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VALTREX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VALTREX:-

You can seek FDA approval to launch a generic drug before the expiration of VFEND's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VFEND's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VFEND:-

You can seek FDA approval to launch a generic drug before the expiration of VIMOVO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIMOVO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIMOVO:-

You can seek FDA approval to launch a generic drug before the expiration of VYTORIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VYTORIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VYTORIN:-

You can seek FDA approval to launch a generic drug before the expiration of ZEGERID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZEGERID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZEGERID:-

You can seek FDA approval to launch a generic drug before the expiration of ZETIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZETIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZETIA:-

You can seek FDA approval to launch a generic drug before the expiration of ZYTIGA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZYTIGA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZYTIGA:-